 - Has received any of the following biologic agents within the following time periods: any marketed immunomodulatory biologic within a period of 3 months or 5 half-lives, whichever is longer, prior to randomization; a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab CNTO 1275, briakinumab ABT-874, guselkumab CNTO 1959 or MK-3222 at any point in time; or an experimental biologic therapy within the previous 6 months 